Download PDF
Geburtshilfe Frauenheilkd 2007; 67(12): 1311-1316
DOI: 10.1055/s-2007-965750
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Therapieoptionen für Patientinnen mit metastasiertem Mammakarzinom nach vorangegangener Anthrazyklin- und Taxanbehandlung

Therapeutic Options for Patients with Anthracycline- and Taxane-Refractory Metastatic Breast CancerS. Hille1 , D. T. Rein1 , P. Dall2 , M. Breidenbach3
  • 1Universitätsfrauenklinik Düsseldorf
  • 2Städtisches Klinikum Lüneburg
  • 3Universitätsfrauenklinik Aachen
Further Information

Publication History

eingereicht 30.5.2007 revidiert 5.9.2007

akzeptiert 6.9.2007

Publication Date:
29 November 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Therapieplanung von Patientinnen mit metastasiertem Mammakarzinom (MMC) nach vorangegangener Behandlung mit Anthrazyklinen und/oder Taxanen stellt eine therapeutische Herausforderung dar. Aufgrund der eingeschränkten Überlebensraten muss die Lebensverlängerung bei langfristigem Erhalt einer guten Lebensqualität das vordringliche Ziel der Therapieplanung sein. Grundsätzlich stehen Monotherapien wegen des günstigeren Nebenwirkungsprofils bei der Therapieauswahl im Vordergrund. Ziel dieser Übersichtsarbeit ist die zusammenfassende Darstellung der aktuellen Datenlage zur Effektivität der verfügbaren Zytostatika sowie neuer targetspezifischer Therapieansätze auf der Basis monoklonaler Antikörper und Tyrosinkinaseinhibitoren.

Abstract

There is an urgent need for agents which are active against anthracycline- and/or taxane-refractory metastatic breast cancer (MBC). Despite the availability of a number of active cytotoxic agents and combination regimens, the survival rates of patients with MBC have not dramatically improved and it remains a largely incurable disease. As such, the goals of treatment in this setting are to maintain or improve the patient's quality of life and to control cancer-related symptoms for as long as possible. An optimal balance between therapy-related toxicities and cancer-controlling benefits is the most important principle to achieve optimal palliation. This review summarizes recent studies on chemotherapy and targeted therapies for anthracycline- and/or taxane-refractory MBC.

Schlüsselwörter

metastasiertes Mammakarzinom - Chemotherapie - anthrazyklinrefraktär - taxanrefraktär

Key words

metastatic breast cancer - anthracycline refractory - taxane refractory - chemotherapy

Literatur

  • 1 Mincey B A, Perez E A. Concise review for clinicians. Advances in screening, diagnosis and treatment of breast cancer.  Mayo Clinic Proceedings. 2004;  76 810-816
    PubMedSearch in Google Scholar
  • 2 Perez E A. Current management of metastatic breast cancer.  Semin Oncol. 1999;  26 1-10
    PubMedSearch in Google Scholar
  • 3 American Cancer Society .Cancer Facts and Figures. Atlanta, GA; American Cancer Society 2003: 9-10
    Search in Google Scholar
  • 4 Sehouli J, Könsgen D, Klapp C, Walle U, Katsares I, Oskay G, Mustea A, Bühling K, Lichtenegger W. Lebensqualität in der gynäkologischen Onkologie. Ein Bericht mit den Ergebnissen des ASCO-Meetings 2002.  Geburtsh Frauenheilk. 2003;  63 752-757
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 O'Brien M ER, Wigler N, Inbar M. et al . Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (caelyx/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.  Ann Oncol. 2004;  15 440-449
    CrossrefPubMedSearch in Google Scholar
  • 6 Keller A M, Mennel R G, Georgoulias V A. et al . Phase III trial of pegylated liposomal doxorubicin versus Vinorelbin or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.  J Clin Oncol. 2004;  22 3893-3901
    CrossrefPubMedSearch in Google Scholar
  • 7 Blum J L, Dieras V, Lo Russo P M, Horton J, Rutman O, Buzdar A, Osterwalder B. Multicenter, phase II study of Capecitabin in taxane-pretreated metastatic breast carcinoma patients.  Cancer. 2001;  92 1759-1768
    CrossrefPubMedSearch in Google Scholar
  • 8 Reichardt P, Von Minckwitz G, Thuss-Patience P C, Jonat W, Kolbl H, Janicke F, Kieback D G, Kuhn W, Schindler A E, Mohrmann S, Kaufmann M, Luck H J. Multicenter phase II study of oral Capecitabin (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.  Ann Oncol. 2003;  14 1227-1233
    CrossrefPubMedSearch in Google Scholar
  • 9 Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere J F, Montestruc F, Mouri Z, Namer M. Multicentre, phase II study evaluating capecitabin monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.  Eur J Cancer. 2004;  40 536-542
    CrossrefPubMedSearch in Google Scholar
  • 10 Miles D, von Minckwitz G, Seidman A D. Combination versus sequential single-agent therapy in metastatic breast cancer.  Oncologist. 2002;  7 13-19
    PubMedSearch in Google Scholar
  • 11 Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R. Safety and efficacy of two different doses of Capecitabin in the treatment of advanced breast cancer in older women.  J Clin Oncol. 2005;  23 2155-2161
    CrossrefPubMedSearch in Google Scholar
  • 12 Udom D I, Vigushin D M, Linardou H, Graham H, Palmieri C, Coombes R C. Two weekly Vinorelbin: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer.  Eur J Cancer. 2000;  36 177-182
    CrossrefPubMedSearch in Google Scholar
  • 13 Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbin-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study.  Cancer Chemother Pharmacol. 1996;  39 150-156
    CrossrefPubMedSearch in Google Scholar
  • 14 Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord J P, Le Cesne A, Spielmann M. Weekly Vinorelbin is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.  Cancer. 2001;  92 2267-2272
    CrossrefPubMedSearch in Google Scholar
  • 15 Livingston R B, Ellis G K, Gralow J R, Williams M A, White R, McGuirt C, Adamkiewicz B B, Long C A. Dose-intensive Vinorelbin with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.  J Clin Oncol. 1997;  15 1395-1400
    PubMedSearch in Google Scholar
  • 16 Jara-Sanchez C, Martin M, Garcia-Saenz J A, Barnada A, Fernandez-Aramburo A, Lopez-Vega J M, Pelegri A, Alba E, Casado A. Spanish Group for Research in Breast Cancer . Vinorelbin as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.  Clin Breast Cancer. 2003;  3 399-404
    PubMedSearch in Google Scholar
  • 17 Verma S, Trudeau M, Dranitsaris G. et al . Survival differences observed in anthracycline and taxane refractory metastatic breast cancer treated with capecitabin when compared to vinorelbine.  Breast Cancer Res Treat. 2004;  88 s201
    PubMedSearch in Google Scholar
  • 18 Tripathy D. Gemcitabine as single agent for therapy of advanced breast cancer.  Clin Breast Cancer. 2002;  3 8-11
    PubMedSearch in Google Scholar
  • 19 Gerson R, Serrano-O A, Villalobos A, Ortiz C, Sánchez-Forgach E. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors.  Proc Am Soc Clin Oncol. 2000;  19
    PubMedSearch in Google Scholar
  • 20 Smorenburg C H, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, de Wit R. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.  Breast Cancer Res Treat. 2001;  66 83-87
    CrossrefPubMedSearch in Google Scholar
  • 21 Perez E A. Carboplatin in combination therapy for metastatic breast cancer.  Oncologist. 2004;  9 518-527
    CrossrefPubMedSearch in Google Scholar
  • 22 Maass N, Bauerschlag D, Eiermann W, Jonat W. Trastzumab-Immuntherapie hält Einzug in die adjuvante Therapie.  Geburtsh Frauenheilk. 2005;  65 1031-1033
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Low J A, Wedam S B, Lee J J, Berman A W, Brufsky A, Yang S X, Poruchynsky M S, Steinberg S M, Mannan N, Fojo T, Swain S M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.  J Clin Oncol. 2005;  23 2726-2734
    PubMedSearch in Google Scholar
  • 24 Breidenbach M, Rimbach S, Rath W, Curiel D T, Rein D T. Transkriptionales Targeting zur zielgerichteten Krebsgentherapie des Mammakarzinoms.  Geburtsh Frauenheilk. 2005;  65 186-191
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Noack F, Krüger S, Hofmann M, Ortmann O. HER‐2-Diagnostik beim Mammakarzinom: Aktuelle Methoden und Zukunftsperspektiven.  Geburtsh Frauenheilk. 2003;  63 1119-1126
    Thieme ConnectPubMedSearch in Google Scholar
  • 26 Piccart-Gebhart M J, Proctor M, Leyland-Jones B. et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 1659-1672
    CrossrefPubMedSearch in Google Scholar
  • 27 Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors.  Nat Med. 2003;  9 669-676
    CrossrefPubMedSearch in Google Scholar
  • 28 Gasparini G, Toi M, Gion M. et al . Prognostic significance of vascular endothelial growth protein in node negative breast carcinoma.  J Natl Cancer Inst. 1997;  89 139-147
    CrossrefPubMedSearch in Google Scholar
  • 29 Schneider B, Miller K. Angiogenesis of breast cancer.  J Clin Oncol. 2005;  23 1782-1790
    CrossrefPubMedSearch in Google Scholar
  • 30 Cobleigh M A, Langmuir V K, Sledge G W. et al . A phase I/II dose escalation of trial of bevacizumab in previously treated metastatic breast cancer.  Semin Oncol. 2003;  30 117-124
    CrossrefPubMedSearch in Google Scholar
  • 31 Miller K, Chap L, Holmes F. et al . Randomized phase-III trial of capecitabin compared with bevacizumab plus capecitabin in patients with previously treated metastatic breast cancer.  J Clin Oncol. 2005;  23 792-799
    CrossrefPubMedSearch in Google Scholar
  • 32 Miller K, Wang M, Gralow J. et al . First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100).  Eur J Cancer Suppl. 2005;  3 77
    PubMedSearch in Google Scholar
  • 33 Koukourakis M I, Giatromanolaki A, O'Byrne K J. et al . BCL‐2 and c-erb-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.  Clin Exp Metastasis. 1999;  17 545-554
    CrossrefPubMedSearch in Google Scholar
  • 34 Pegram M, Yeon C, Ku N. et al . Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 protooncogene and vascular endothelial growth factor (VEGF).  Breast Cancer Res Treat. 2004;  88 124
    PubMedSearch in Google Scholar
  • 35 Rugo H, Dickler M, Scott J. et al . Circulating endothelial cell (CEC) and tumor cell (CTC) analysis in patients receiving bevacizumab and erlotinib for metastatic breast cancer (MBC).  Breast Cancer Res Treat. 2004;  88 142
    PubMedSearch in Google Scholar
  • 36 Petit A M, Rak J, Hung M C. et al . Neutralizing antibodies against epidermal growth factor and erbB‐2/neu receptor kinases down regulate vascular endothelial growth factor production by tumour cells in vitro and in vivo : angiogenic implications for signal transduction therapy of solid tumors.  Am J Pathol. 1997;  151 1523-1530
    PubMedSearch in Google Scholar
  • 37 Nahta R, Hung M C, Esteva F J. et al . The HER2 targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.  Cancer Res. 2004;  64 2343-2346
    CrossrefPubMedSearch in Google Scholar
  • 38 Blackwell K L, Kaplan E H, Franco S X, Marcom P K, Maleski J E, Sorensen M J, Berger M S. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology, 2004 (July 15 Supplement) ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 22, No 14S. 
  • 39 Lin Nu, Winer E P. New targets for therapy in breast cancer: small molecule tyrosine kinaseinhibitors.  Breast Cancer Res. 2004;  6 204-210
    CrossrefPubMedSearch in Google Scholar
  • 40 Albain K, Elledge R, Gradishar W J. et al . Open label Phase II, multi-centre trial of ZD 1839 (“Iressa”) in patients with advanced breast cancer.  Breast Cancer Res Treat. 2002;  76 S33
    PubMedSearch in Google Scholar
  • 41 Roberston J FR, Gutteridge E, Cheung K L. et al . Gefitinib (ZD1839) is active in aquired tamoxifen (TAM) resistant oestrogen receptor (ER)-positive and ER negative breast cancer: results from a Phase II study.  Proc Am Soc Clin Oncol. 2003;  22 7-(Abstract 23)
    PubMedSearch in Google Scholar
  • 42 Baselga J, Albanell J, Ruiz A. et al . Phase II and tumour pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer.  Proc Am Soc Clin Oncol. 2003;  22 7
    PubMedSearch in Google Scholar
  • 43 Kim E S, Khuri F R, Herbst R S. et al . Epidermal growth factor receptor biology (IMC-C225).  Curr Opin Oncol. 2001;  13 506-513
    CrossrefPubMedSearch in Google Scholar

Priv.-Doz. Dr. Martina Breidenbach

Universitätsfrauenklinik Aachen

Pauwelsstraße 30

52074 Aachen

Email: mbreidenbach@ukaachen.de